GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Whitehawk Therapeutics Inc (NAS:WHWK) » Definitions » PS Ratio

WHWK (Whitehawk Therapeutics) PS Ratio : 2.11 (As of Jul. 06, 2025)


View and export this data going back to 2021. Start your Free Trial

What is Whitehawk Therapeutics PS Ratio?

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Whitehawk Therapeutics's share price is $1.99. Whitehawk Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2025 was $0.94. Hence, Whitehawk Therapeutics's PS Ratio for today is 2.11.

The historical rank and industry rank for Whitehawk Therapeutics's PS Ratio or its related term are showing as below:

WHWK' s PS Ratio Range Over the Past 10 Years
Min: 1.51   Med: 6.95   Max: 510.63
Current: 2.11

During the past 5 years, Whitehawk Therapeutics's highest PS Ratio was 510.63. The lowest was 1.51. And the median was 6.95.

WHWK's PS Ratio is ranked better than
84.81% of 968 companies
in the Biotechnology industry
Industry Median: 9.395 vs WHWK: 2.11

Whitehawk Therapeutics's Revenue per Sharefor the three months ended in Mar. 2025 was $0.18. Its Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2025 was $0.94.

During the past 12 months, the average Revenue per Share Growth Rate of Whitehawk Therapeutics was 6.40% per year. During the past 3 years, the average Revenue per Share Growth Rate was 104.70% per year.

During the past 5 years, Whitehawk Therapeutics's highest 3-Year average Revenue per Share Growth Rate was 104.70% per year. The lowest was 10.40% per year. And the median was 57.55% per year.

Back to Basics: PS Ratio


Whitehawk Therapeutics PS Ratio Historical Data

The historical data trend for Whitehawk Therapeutics's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Whitehawk Therapeutics PS Ratio Chart

Whitehawk Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
PS Ratio
- 215.63 18.98 2.23 3.28

Whitehawk Therapeutics Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.64 1.65 2.22 3.28 1.89

Competitive Comparison of Whitehawk Therapeutics's PS Ratio

For the Biotechnology subindustry, Whitehawk Therapeutics's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Whitehawk Therapeutics's PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Whitehawk Therapeutics's PS Ratio distribution charts can be found below:

* The bar in red indicates where Whitehawk Therapeutics's PS Ratio falls into.


;
;

Whitehawk Therapeutics PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

Whitehawk Therapeutics's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=1.99/0.942
=2.11

Whitehawk Therapeutics's Share Price of today is $1.99.
Whitehawk Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.94.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


Whitehawk Therapeutics  (NAS:WHWK) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


Whitehawk Therapeutics PS Ratio Related Terms

Thank you for viewing the detailed overview of Whitehawk Therapeutics's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Whitehawk Therapeutics Business Description

Traded in Other Exchanges
Address
2 Headquarters Plaza East Building, 11th Floor, Morristown, New Jersey, NJ, USA, 07960
Whitehawk Therapeutics Inc is a preclinical stage oncology therapeutics. The company is engaged in applying technologies to established tumor biology to efficiently deliver improved cancer treatments. The company's three-asset ADC portfolio is engineered to overcome the limitations of first-generation predecessors to deliver a meaningful impact for patients with difficult-to-treat cancers.
Executives
David James Lennon director, officer: Chief Executive Officer C/O AADI BIOSCIENCE, INC., 17383 SUNSET BLVD, SUITE A250, PACIFIC PALISADES CA 90272
Scott M. Giacobello officer: Chief Financial Officer SOVEREIGN HOUSE, VISION PARK, HISTON, CAMBRIDGE X0 CB24 9BZ
Neil Desai director, officer: See Remarks C/O AADI BIOSCIENCE, INC., 17383 SUNSET BLVD., SUITE A250, PACIFIC PALISADES CA 90272
Mohammad Hirmand director C/O MEDIVATION, INC., 525 MARKET ST., 36TH FLOOR, SAN FRANCISCO CA 94105
Lorettta M Itri officer: Chief Medical Officer
Brendan Delaney officer: Chief Operating Officer 300 THE AMERICAN WAY, MORRIS PLAINS NJ 07950
Emma Reeve director C/O PAREXEL INTERNATIONAL CORPORATION, 195 WEST STREET, WALTHAM MA 02451
Karin M. Hehenberger director C/O CORONADO BIOSCIENCES, INC., 15 NEW ENGLAND EXECUTIVE PARK, BURLINGTON CO 01803
Richard E Maroun director C/O AADI BIOSCIENCE, INC., 17383 SUNSET BLVD., SUITE A250, PACIFIC PALISADES CA 90272
Caley Castelein director THOM. WEISEL HEALTHCARE VENTURES, ONE MONTGOMERY STREET, SAN FRANCISCO CA 94104
Lance E Thibault officer: Chief Financial Officer
Behzad Aghazadeh director, other: See Remarks C/O AVORO CAPITAL ADVISORS LLC, 110 GREENE STREET, SUITE 800, NEW YORK NY 10012
Venbio Select Advisor Llc director, other: See Remarks 110 GREENE STREET, SUITE 800, NEW YORK NY 10012
Anupam Dalal director 88 KEARNY STREET, SUITE 1800, SAN FRANCISCO CA 94108
Avoro Ventures Llc director, other: See Remarks 110 GREEN STREET, SUITE 800, NEW YORK NY 10012